Nederlands tijdschrift voor geneeskunde · 2013
[A man with colorectal signet ring cell carcinoma: which therapy is required?].
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dietvorst M H P Anne-Marie, Schoenmakers Noortje, ten Tije Albert J
Аннотация
BACKGROUND: Primary colorectal signet ring cell carcinoma (SRCC) is rare and often affects younger patients. It demonstrates a different biological behaviour and has a less favourable prognosis than the more conventional colorectal adenocarcinoma.
CASE DESCRIPTION: Patient A, a 65-year-old man, presented with a change in bowel habit. Colonoscopy showed a stenosis with signs of a nonspecific inflammation. However, laparoscopy revealed a primary colorectal SRCC with diffuse peritoneal metastases. Standard chemotherapy was unsuccessful. Patient A died 13 months after diagnosis.
CONCLUSION: Based on clinical and molecular differences, SRCC can be recognized as a separate subtype of colorectal cancer. The case description illustrates that this group of patients may benefit from a different management strategy than the usual therapy. A greater understanding of the characteristics of this specific malignancy is needed.
CASE DESCRIPTION: Patient A, a 65-year-old man, presented with a change in bowel habit. Colonoscopy showed a stenosis with signs of a nonspecific inflammation. However, laparoscopy revealed a primary colorectal SRCC with diffuse peritoneal metastases. Standard chemotherapy was unsuccessful. Patient A died 13 months after diagnosis.
CONCLUSION: Based on clinical and molecular differences, SRCC can be recognized as a separate subtype of colorectal cancer. The case description illustrates that this group of patients may benefit from a different management strategy than the usual therapy. A greater understanding of the characteristics of this specific malignancy is needed.